|
1
|
Rong Y, Bentley JP, Bhattacharya K, Yang
Y, Chang Y, Earl S and Ramachandran S: Incidence and risk factors
of immune-related adverse events induced by immune checkpoint
inhibitors among older adults with non-small cell lung cancer.
Cancer Med. 13:e68792024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ito K, Hashimoto K, Kaira K, Yamaguchi O,
Mouri A, Shiono A, Miura Y, Kobayashi K, Imai H, Kuji I and Kagamu
H: Clinical impact of inflammatory and nutrition index based on
metabolic tumor activity in non-small cell lung cancer treated with
immunotherapy. Oncol Lett. 27:1102024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen P, Liu Y, Wen Y and Zhou C: Non-small
cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
González-Cao M, Cai X, Bracht JWP, Han X,
Yang Y, Pedraz-Valdunciel C, Morán T, García-Corbacho J, Aguilar A,
Bernabé R, et al: hmgb1 expression levels correlate with response
to immunotherapy in non-small cell lung cancer. Lung Cancer
(Auckl). 15:55–67. 2024.PubMed/NCBI
|
|
5
|
Zhang CL, Gao MQ, Jiang XC, Pan X, Zhang
XY, Li Y, Shen Q, Chen Y and Pang B: Research progress and value of
albumin-related inflammatory markers in the prognosis of non-small
cell lung cancer: A review of clinical evidence. Ann Med.
55:1294–1307. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sorin M, Prosty C, Ghaleb L, Nie K,
Katergi K, Shahzad MH, Dubé LR, Atallah A, Swaby A, Dankner M, et
al: Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review
and meta-analysis. JAMA Oncol. 10:621–633. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herrera-Juárez M, Serrano-Gómez C,
Bote-de-Cabo H and Paz-Ares L: Targeted therapy for lung cancer:
Beyond EGFR and ALK. Cancer. 129:1803–1820. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Remon J, Besse B, Aix SP, Callejo A,
Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, et
al: Osimertinib treatment based on plasma T790M monitoring in
patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC
Lung Cancer Group 1613 APPLE phase II randomized clinical trial.
Ann Oncol. 34:468–476. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun L, Bleiberg B, Hwang WT, Marmarelis
ME, Langer CJ, Singh A, Cohen RB, Mamtani R and Aggarwal C:
Association between duration of immunotherapy and overall survival
in advanced non-small cell lung cancer. JAMA Oncol. 9:1075–1082.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiang Y, Liu X, Wang Y, Zheng D, Meng Q,
Jiang L, Yang S, Zhang S, Zhang X, Liu Y and Wang B: Mechanisms of
resistance to targeted therapy and immunotherapy in non-small cell
lung cancer: Promising strategies to overcoming challenges. Front
Immunol. 15:13662602024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Niu M, Yi M, Li N, Luo S and Wu K:
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp
Hematol Oncol. 10:182021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen
L and Zhou J: The progress and challenge of anti-PD-1/PD-L1
immunotherapy in treating non-small cell lung cancer. Ther Adv Med
Oncol. 13:17588359219929682021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Castro G Jr, Kudaba I, Wu YL, Lopes G,
Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B,
Laktionov KK, et al: Five-year outcomes with pembrolizumab versus
chemotherapy as first-line therapy in patients with non-small-cell
lung cancer and programmed death ligand-1 tumor proportion score ≥
1% in the KEYNOTE-042 study. J Clin Oncol. 41:1986–1991. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Socinski MA, Nishio M, Jotte RM, Cappuzzo
F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D,
Moro-Sibilot D, Thomas CA, et al: IMpower150 final overall survival
analyses for atezolizumab plus bevacizumab and chemotherapy in
first-line metastatic nonsquamous NSCLC. J Thorac Oncol.
16:1909–1924. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Yang Y, Yu J, Zhang S, Li X, Wu X,
Nie X, Liu W, Zhang P, Li Y, et al: Efficacy and safety of
anti-PD-1/PD-L1 in combination with chemotherapy or not as
first-line treatment for advanced non-small cell lung cancer: A
systematic review and network meta-analysis. Thorac Cancer.
13:322–337. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Q, Wang W, Yuan Q, Li L, Wang YC,
Chi CZ and Xu CH: Correlation between immune-related adverse events
and the efficacy of PD-1/PD-L1 inhibitors in the treatment of
non-small cell lung cancer: Systematic review and meta-analysis.
Cancer Chemother Pharmacol. 89:1–9. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma YT, Hua F, Zhong XM, Xue YJ, Li J, Nie
YC, Zhang XD, Ma JW, Lin CH, Zhang HZ, et al: Clinicopathological
characteristics, molecular landscape, and biomarker landscape for
predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese
population with mismatch repair deficient urothelial carcinoma: A
real-world study. Front Immunol. 14:12690972023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu
K: Combination strategies with PD-1/PD-L1 blockade: Current
advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bie F, Tian H, Sun N, Zang R, Zhang M,
Song P, Liu L, Peng Y, Bai G, Zhou B and Gao S: Research progress
of anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive
biomarkers in NSCLC. Front Oncol. 12:7691242022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zurlo IV, Schino M, Strippoli A, Calegari
MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R,
Barone C, et al: Predictive value of NLR, TILs (CD4+/CD8+) and
PD-L1 expression for prognosis and response to preoperative
chemotherapy in gastric cancer. Cancer Immunol Immunother.
71:45–55. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanus M, Parada-Venegas D, Landskron G,
Wielandt AM, Hurtado C, Alvarez K, Hermoso MA, López-Köstner F and
De la Fuente M: Immune system, microbiota, and microbial
metabolites: The unresolved triad in colorectal cancer
microenvironment. Front Immunol. 12:6128262021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu Y, Yuan X, Wang M, He Z, Li H, Wang J
and Li Q: Gut microbiota influence immunotherapy responses:
Mechanisms and therapeutic strategies. J Hematol Oncol. 15:472022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou CB, Zhou YL and Fang JY: Gut
microbiota in cancer immune response and immunotherapy. Trends
Cancer. 7:647–660. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao G, Shen S, Zhang T, Zhang J, Huang S,
Sun Z and Zhang H: Lacticaseibacillus rhamnosus Probio-M9 enhanced
the antitumor response to anti-PD-1 therapy by modulating
intestinal metabolites. EBioMedicine. 91:1045332023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mifsud EJ, Kuba M and Barr IG: Innate
immune responses to influenza virus infections in the upper
respiratory tract. Viruses. 13:20902021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wiesweg M, Mairinger F, Reis H, Goetz M,
Kollmeier J, Misch D, Stephan-Falkenau S, Mairinger T, Walter RFH,
Hager T, et al: Machine learning reveals a PD-L1-independent
prediction of response to immunotherapy of non-small cell lung
cancer by gene expression context. Eur J Cancer. 140:76–85. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chai J, Capik SF, Kegley B, Richeson JT,
Powell JG and Zhao J: Bovine respiratory microbiota of feedlot
cattle and its association with disease. Vet Res. 53:42022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seymour L, Bogaerts J, Perrone A, Ford R,
Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et
al: iRECIST: Guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 18:e143–e152. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K,
Han R, Qiao M, Li W, Yu J, et al: Patients with short PFS to
EGFR-TKIs predicted better response to subsequent anti-PD-1/PD-L1
based immunotherapy in EGFR common mutation NSCLC. Front Oncol.
11:6399472021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klindworth A, Pruesse E, Schweer T,
Peplies J, Quast C, Horn M and Glöckner FO: Evaluation of general
16S ribosomal RNA gene PCR primers for classical and
next-generation sequencing-based diversity studies. Nucleic Acids
Res. 41:e12013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weiss S, Xu ZZ, Peddada S, Amir A,
Bittinger K, Gonzalez A, Lozupone C, Zaneveld JR, Vázquez-Baeza Y,
Birmingham A, et al: Normalization and microbial differential
abundance strategies depend upon data characteristics. Microbiome.
5:272017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin
Y, Wang W, Tang W, Tan Z, Shi J, et al: Altered fecal microbiota
composition in patients with major depressive disorder. Brain Behav
Immun. 48:186–194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Routy B, Le Chatelier E, Derosa L, Duong
CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C,
Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based
immunotherapy against epithelial tumors. Science. 359:91–97. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tiffeau-Mayer A: Unbiased estimation of
sampling variance for Simpson's diversity index. Phys Rev E.
109:0644112024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dou XJ, Ma RY, Ren DW, Liu Q and Yan P:
Effectiveness and safety of anlotinib combined with PD-1 blockades
in patients with previously immunotherapy treated advanced
non-small cell lung cancer: A retrospective exploratory study. Lung
Cancer (Auckl). 15:29–40. 2024.PubMed/NCBI
|
|
36
|
Li C, Lei S, Ding L, Xu Y, Wu X, Wang H,
Zhang Z, Gao T, Zhang Y and Li L: Global burden and trends of lung
cancer incidence and mortality. Chin Med J (Engl). 136:1583–1590.
2023.PubMed/NCBI
|
|
37
|
Brozos-Vázquez EM, Díaz-Peña R,
García-González J, León-Mateos L, Mondelo-Macía P, Peña-Chilet M
and López-López R: Immunotherapy in nonsmall-cell lung cancer:
Current status and future prospects for liquid biopsy. Cancer
Immunol Immunother. 70:1177–1188. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Himuro H, Nakahara Y, Igarashi Y, Kouro T,
Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K,
et al: Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC
patients treated with immune checkpoint inhibitors. Cancer Immunol
Immunother. 72:2829–2840. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Herbst RS, Garon EB, Kim DW, Cho BC,
Gervais R, Perez-Gracia JL, Han JY, Majem M, Forster MD, Monnet I,
et al: Five year survival update from KEYNOTE-010: Pembrolizumab
Versus docetaxel for previously treated, programmed death-ligand
1-positive advanced NSCLC. J Thorac Oncol. 16:1718–1732. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shah MA, Kojima T, Hochhauser D, Enzinger
P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT,
et al: Efficacy and safety of pembrolizumab for heavily pretreated
patients with advanced, metastatic adenocarcinoma or squamous cell
carcinoma of the esophagus: The phase 2 KEYNOTE-180 study. JAMA
Oncol. 5:546–550. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li XP, Zhang WD, Li MJ, Wang J, Lian J and
Zhou HG: Effectiveness and Safety of PD-1 Inhibitor Monotherapy for
Elderly Patients with Advanced Non-Small Cell Lung Cancer: A
Real-World Exploratory Study. J Oncol. 2022:17102722022.PubMed/NCBI
|
|
42
|
Peng L, Wang Y, Liu F, Qiu X, Zhang X,
Fang C, Qian X and Li Y: Peripheral blood markers predictive of
outcome and immune-related adverse events in advanced non-small
cell lung cancer treated with PD-1 inhibitors. Cancer Immunol
Immunother. 69:1813–1822. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomised phase 3 trial. Lancet.
384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheng JD, Chai LX, Zhao ZP, Hao YY and Li
S: Efficacy and safety of anlotinib for patients with advanced
NSCLC who progressed after standard regimens and the preliminary
analysis of an efficacy predictor. Cancer Manag Res. 12:5641–5650.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Velcheti V, Chandwani S, Chen X, Pietanza
MC and Burke T: First-line pembrolizumab monotherapy for metastatic
PD-L1-positive NSCLC: Real-world analysis of time on treatment.
Immunotherapy. 11:889–901. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Han B, Li K, Wang Q, Zhang L, Shi J, Wang
Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a
third-line or further treatment on overall survival of patients
with advanced non-small cell lung cancer: The ALTER 0303 phase 3
randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Apopa PL, Alley L, Penney RB, Arnaoutakis
K, Steliga MA, Jeffus S, Bircan E, Gopalan B, Jin J,
Patumcharoenpol P, et al: PARP1 Is up-regulated in non-small cell
lung cancer tissues in the presence of the cyanobacterial toxin
microcystin. Front Microbiol. 9:17572018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cameron SJS, Lewis KE, Huws SA, Hegarty
MJ, Lewis PD, Pachebat JA and Mur LAJ: A pilot study using
metagenomic sequencing of the sputum microbiome suggests potential
bacterial biomarkers for lung cancer. PLoS One. 12:e01770622017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, Xu
X, Zhao Z, Lv J and Li Z: Gegen Qinlian decoction enhances the
effect of PD-1 blockade in colorectal cancer with microsatellite
stability by remodelling the gut microbiota and the tumour
microenvironment. Cell Death Dis. 10:4152019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gopalakrishnan V, Spencer CN, Nezi L,
Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman
K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1
immunotherapy in melanoma patients. Science. 359:97–103. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen
Y, Zheng H, Yao C, Wang Y and Lu S: The diversity of gut microbiome
is associated with favorable responses to anti-programmed death 1
immunotherapy in Chinese patients With NSCLC. J Thorac Oncol.
14:1378–1389. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jang HJ, Choi JY, Kim K, Yong SH, Kim YW,
Kim SY, Kim EY, Jung JY, Kang YA, Park MS, et al: Relationship of
the lung microbiome with PD-L1 expression and immunotherapy
response in lung cancer. Respir Res. 22:3222021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
